LncRNA AC005332.7 Inhibited Ferroptosis to Alleviate Acute Myocardial Infarction Through Regulating miR-331-3p/CCND2

Rixin Dai1, Xiheng Yang2, Wujin He2

  • 1Department of Cardiology, The Affiliated Hospital of Guilin Medical University, Guilin, P.R. China. drx@glmc.edu.cn.

Abstract

Insights

AC005332.7 inhibits ferroptosis and protects against acute myocardial infarction (AMI) by targeting the miR-331-3p/CCND2 pathway. This finding offers new therapeutic targets for treating AMI and reducing heart damage.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Cellular Pathology

Background:

  • Acute myocardial infarction (AMI) is a sudden, life-threatening condition.
  • Ferroptosis, a regulated cell death pathway, is implicated in AMI progression.
  • The precise role and mechanisms of ferroptosis in AMI require elucidation.

Purpose of the Study:

  • To investigate the role of AC005332.7 in ferroptosis during AMI.
  • To elucidate the molecular mechanism by which AC005332.7 influences ferroptosis in AMI.
  • To identify potential therapeutic targets for AMI treatment.

Main Methods:

  • Established in vitro (AC16 cells, oxygen-glucose deprivation) and in vivo (LAD ligation mice) models of AMI.
  • Assessed cell viability, lactate dehydrogenase, creatine kinase, reactive oxygen species (ROS), glutathione (GSH), malondialdehyde (MDA), and iron levels.
  • Utilized dual luciferase reporter gene assay, RNA-binding protein immunoprecipitation, and RNA pull-down to validate molecular interactions.
  • Performed hematoxylin and eosin staining to evaluate myocardial damage.

Main Results:

  • AC005332.7 and cyclin D2 (CCND2) were downregulated, while miR-331-3p was upregulated in AMI models.
  • AC005332.7 overexpression reduced ferroptosis markers (ROS, MDA, iron) and increased protective markers (GSH, GPX4), mitigating cardiomyocyte injury.
  • AC005332.7 interacted with miR-331-3p, which targeted CCND2, mediating the anti-ferroptosis effect.

Conclusions:

  • AC005332.7 suppresses ferroptosis in AMI by modulating the miR-331-3p/CCND2 axis.
  • This mechanism alleviates cardiomyocyte injury in AMI.
  • AC005332.7 represents a potential therapeutic target for AMI treatment.